Melatonin promotes puromycin-induced apoptosis with activation of caspase-3 and 5′-adenosine monophosphate-activated kinase-alpha in human leukemia HL-60 cells

Journal of Pineal Research

Volumn 50, Issue 4, 2011, Pages 367-373

  Koh, Wonil ^a   Jeong, Soo Jin ^a   Lee, Hyo Jung ^a   Ryu, Ho Geon ^a   Lee, Eun Ok ^a   Ahn, Kyoo Seok ^a   Bae, Hyunsu ^a   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

Author keywords

5 adenosine monophosphate activated kinase alpha; apoptosis; checkpoint kinase; HL 60 cells; melatonin; puromycin

Indexed keywords

5' ADENOSINE MONOPHOSPHATE ACTIVATED KINASE ALPHA; ADENOSINE PHOSPHATE; CASPASE 3; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; MELATONIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; PUROMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN HL 60; CELL SUBPOPULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

AMP-ACTIVATED PROTEIN KINASES; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; HL-60 CELLS; HUMANS; MELATONIN; PUROMYCIN;

EID: 79954422774     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2010.00852.x     Document Type: Article

References (56)

1. Altun A, Ugur-Altun B,. Melatonin: therapeutic and clinical utilization. Int J Clin Pract 2007; 61: 835-845. (Pubitemid 46587862)
2. Reiter RJ, Tan DX, Fuentes-Broto L,. Melatonin: a multitasking molecule. Prog Brain Res 2010; 181: 127-151.
3. Tan DX, Chen LD, Poeggeler B, et al., Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1: 57-60.
4. Carrillo-Vico A, Guerrero JM, Lardone PJ, et al., A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200. (Pubitemid 41558451)
5. Hardeland R, Tan DX, Reiter RJ,. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009; 47: 109-126.
6. Mills E, Wu P, Seely D, et al., Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 2005; 39: 360-366.
7. Tan DX, Manchester LC, Fuentes-Broto L, et al., Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes Rev 2010; [Epub ahead of print].
8. Leja-Szpak A, Jaworek J, Pierzchalski P, et al., Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res 2010; 49: 248-255.
9. Fan LL, Sun GP, Wei W, et al., Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World J Gastroenterol 2010; 16: 1473-1481.
10. Casado-Zapico S, Rodriguez-Blanco J, Garcia-Santos G, et al., Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway. J Pineal Res 2010; 48: 72-80.
11. Martin V, Garcia-Santos G, Rodriguez-Blanco J, et al., Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death. Cancer Lett 2010; 287: 216-223.
12. Joo SS, Yoo YM,. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res 2009; 47: 8-14.
13. Grignani F, Fagioli M, Alcalay M, et al., Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10-25. (Pubitemid 24016510)
14. Melnick A, Licht JD,. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-3215. (Pubitemid 29220886)
15. Drexler HG, Quentmeier H, Macleod RA, et al., Leukemia cell lines: in vitro models for the study of acute promyelocytic leukemia. Leuk Res 1995; 19: 681-691.
16. Liu P, Han ZC,. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies. Int J Hematol 2003; 78: 32-39. (Pubitemid 36899899)
17. Frankel SR, Eardley A, Lauwers G, et al., The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-296.
18. Fenaux P, De Botton S,. Retinoic acid syndrome. Recognition, prevention and management. Drug Saf 1998; 18: 273-279. (Pubitemid 28177291)
19. Avvisati G, Lo Coco F, Diverio D, et al., AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390-1398. (Pubitemid 26276815)
20. Bejarano I, Redondo PC, Espino J, et al., Melatonin induces mitochondrial-mediated apoptosis in human myeloid HL-60 cells. J Pineal Res 2009; 46: 392-400.
21. Suter M, Riek U, Tuerk R, et al., Dissecting the role of 5′-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem 2006; 281: 32207-32216. (Pubitemid 46036775)
22. Hardie DG, Scott JW, Pan DA, et al., Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 2003; 546: 113-120. (Pubitemid 36782291)
23. Zhang WB, Wang Z, Su F, et al., Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem 2010; 285: 40461-40471.
24. Kim HJ, Kim SK, Kim BS, et al., Apoptotic effect of quercetin on HT-29 colon cancer cells via the AMPK signaling pathway. J Agric Food Chem 2010; 58: 8643-8650.
25. Hsu YC, Meng X, Ou L, et al., Activation of the AMP-activated protein kinase-p38 MAP kinase pathway mediates apoptosis induced by conjugated linoleic acid in p53-mutant mouse mammary tumor cells. Cell Signal 2010; 22: 590-599.
26. Takagaki K, Katsuma S, Kaminishi Y, et al., Role of Chk1 and Chk2 in Ara-C-induced differentiation of human leukemia K562 cells. Genes Cells 2005; 10: 97-106. (Pubitemid 40287513)
27. Pietenpol JA, Stewart ZA,. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology 2002; 182: 475-481. (Pubitemid 36015741)
28. Bartek J, Lukas J,. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-429. (Pubitemid 38340288)
29. Abraham RT,. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15: 2177-2196. (Pubitemid 32843830)
30. Syljuasen RG, Sorensen CS, Nylandsted J, et al., Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation. Cancer Res 2004; 64: 9035-9040. (Pubitemid 39665514)
31. Chen C, Shimizu S, Tsujimoto Y, et al., Chk2 regulates transcription-independent p53-mediated apoptosis in response to DNA damage. Biochem Biophys Res Commun 2005; 333: 427-431. (Pubitemid 40848308)
32. Niida H, Murata K, Shimada M, et al., Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo. EMBO J 2010; 29: 3558-3570.
33. Ahn Q, Jeong SJ, Lee HJ, et al., Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cells. Cancer Lett 2010; 298: 212-221.
34. Won SH, Lee HJ, Jeong SJ, et al., Tanshinone IIA induces mitochondria dependent apoptosis in prostate cancer cells in association with an inhibition of phosphoinositide 3-kinase/AKT pathway. Biol Pharm Bull 2010; 33: 1828-1834.
35. Konopleva M, Zhao S, Xie Z, et al., Apoptosis. Molecules and mechanisms. Adv Exp Med Biol 1999; 457: 217-236.
36. Hillestad LK,. Acute promyelocytic leukemia. Acta Med Scand 1957; 159: 189-194.
37. Wang ZY, Chen Z,. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505-2515.
38. Asou N, Kishimoto Y, Kiyoi H, et al., A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007; 110: 59-66. (Pubitemid 47026819)
39. Sanz MA, Martin G, Gonzalez M, et al., Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237-1243. (Pubitemid 38168633)
40. Rubio S, Estevez F, Cabrera J, et al., Inhibition of proliferation and induction of apoptosis by melatonin in human myeloid HL-60 cells. J Pineal Res 2007; 42: 131-138. (Pubitemid 46233058)
41. Majno G, Joris I,. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995; 146: 3-15.
42. Sanli T, Rashid A, Liu C, et al., Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys 2010; 78: 221-229.
43. Hadad SM, Fleming S, Thompson AM,. Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 2008; 67: 1-7.
44. Fogarty S, Hardie DG,. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 2010; 1804: 581-591.
45. Jalving M, Gietema JA, Lefrandt JD, et al., Metformin: taking away the candy for cancer? Eur J Cancer 2010; 46: 2369-2380.
46. Kilbride SM, Farrelly AM, Bonner C, et al., AMP-activated protein kinase mediates apoptosis in response to bioenergetic stress through the activation of the pro-apoptotic BH3-only protein BMF. J Biol Chem 2010; 285: 36199-36206.
47. Kwon KJ, Kim HJ, Shin CY, et al., Melatonin Potentiates the Neuroprotective Properties of Resveratrol Against Beta-Amyloid-Induced Neurodegeneration by Modulating AMP-Activated Protein Kinase Pathways. J Clin Neurol 2010; 6: 127-137.
48. Liu Q, Guntuku S, Cui XS, et al., Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000; 14: 1448-1459. (Pubitemid 30421838)
49. Takai H, Tominaga K, Motoyama N, et al., Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev 2000; 14: 1439-1447. (Pubitemid 30421837)
50. Ng CP, Lee HC, Ho CW, et al., Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains. J Biol Chem 2004; 279: 8808-8819. (Pubitemid 38295939)
51. Verlinden L, Vanden Bempt I, Eelen G, et al., The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor /HER-2 breast carcinomas. Cancer Res 2007; 67: 6574-6581. (Pubitemid 47105501)
52. Merry C, Fu K, Wang J, et al., Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle 2010; 9: 279-283.
53. PIRES IM, WARD TH, DIVE C,. Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors. Br J Pharmacol 2010; 159: 1326-1338.
54. Zaugg K, Su YW, Reilly PT, et al., Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. Proc Natl Acad Sci U S A 2007; 104: 3805-3810. (Pubitemid 47181535)
55. Vogel C, Kienitz A, Hofmann I, et al., Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 2004; 23: 6845-6853. (Pubitemid 39279985)
56. Reiter RJ, Tan DX, Sainz RM, et al., Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54: 1299-1321. (Pubitemid 35174175)